Suven Life Scie. Q1 FY27 Results (NSE: SUVEN)
Signal: Loss widened
The read
The trajectory remains investment-heavy rather than commercially scaling: revenue rose 91.0% YoY to ₹356.58 lakh, but consolidated R&D expense grew 198.5% YoY to ₹12,383.10 lakh and the PAT loss widened 147.7% to ₹12,761.03 lakh; the key inflection is clinical progress, not near-term operating profitability, with SUVN-502 at 95% enrolment and SUVN-G3031 entering Phase 3.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹3.57 Cr | +91.0% | +134.6% |
| EBIT | ₹-127.13 Cr | -146.8% | |
| Net profit | ₹-127.61 Cr | -147.7% | |
| EPS | ₹-4.84 | -105.1% | |
| EBIT margin | -3500.8% |
P&L walk
Consolidated revenue increased to ₹356.58 lakh, +91.0% YoY and +134.6% QoQ, but R&D expense rose to ₹12,383.10 lakh, +198.5% YoY, driving EBITDA margin to -3500.8% from approximately -2714% a year earlier and PAT loss to ₹12,761.03 lakh from ₹5,151.69 lakh.
Segments
The company reports one business segment, Research & Development, but consolidated loss of ₹12,761.03 lakh versus standalone loss of ₹1,611.91 lakh shows that the wholly owned subsidiary Suven Neurosciences, Inc. is dragging group earnings by ₹11,149.11 lakh.
Key positives
- SUVN-502 (Masupirdine) reached 95% enrolment in its global Phase 3 Alzheimer’s agitation trial, with enrolment expected to complete by end-September 2026.
- SUVN-G3031 (Samelisant) began a global Phase 3 trial for excessive daytime sleepiness in narcolepsy in April 2026.
- SUVN-911 completed its Phase 2b trial in major depressive disorder, while SUVN-I6107 completed Phase 1 and is being prepared for Phase 2.
- Preferential-issue proceeds of ₹85,764.02 lakh were received, with ₹44,813.73 lakh unutilised at quarter-end, providing funding visibility for clinical development.
Key concerns
- Consolidated PAT loss widened to ₹12,761.03 lakh, -147.7% YoY, despite revenue growth of 91.0%.
- R&D expense rose 198.5% YoY to ₹12,383.10 lakh, equivalent to 1117.2% of total income, keeping EBITDA margin at -3500.8%.
- The wholly owned subsidiary reported ₹11,149.11 lakh loss on nil revenue, creating a ₹11,149.12 lakh gap between consolidated and standalone losses.
- Revenue remains small at ₹356.58 lakh and lacks disclosed volume, product or collaboration economics, so clinical progress has not yet translated into operating scale.
- Finance costs increased to ₹47.61 lakh from nil a year earlier, while depreciation rose 57.5% YoY to ₹215.51 lakh.
Research and educational content only. Not investment advice.